Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 9/20 | 0.53 |
| ▸ | RHOC | P08134 | 1/20 | 0.49 |
| ▸ | RHOA | P61586 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10282497 | 0.83 | F10 (0.55) | F10RHOCRHOAHPGDTSHR | |
| SCHEMBL1106579 | 0.83 | HPGD (0.47) | F10HPGDTSHRLMNATP53 | |
| SCHEMBL1097423 | 0.81 | F10 (0.56) | F10RHOCRHOAHPGDTSHR | |
| SCHEMBL1096846 | 0.80 | F10 (0.53) | F10RHOCRHOAHPGDTSHR | |
| SCHEMBL1097619 | 0.80 | F10 (0.53) | F10RHOCRHOAHPGDTSHR | |
| SCHEMBL1106585 | 0.80 | HPGD (0.46) | F10HPGDTSHRLMNAKDM4E | |
| SCHEMBL4947618 | 0.79 | F10 (0.52) | F10RHOCRHOAHPGDTSHR | |
| SCHEMBL1096804 | 0.79 | F10 (0.52) | F10RHOCRHOAHPGDTSHR | |
| SCHEMBL1096188 | 0.78 | F10 (0.53) | F10RHOCRHOAHPGDTSHR | |
| SCHEMBL1106607 | 0.77 | F10 (0.46) | F10HPGDTSHRLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153670-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298806-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | F10 8/4885RHOC 3774/4885RHOA 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.